A pivotal phase III trial of Proxinium (VB4-847) in patients with head and neck cancer

Trial Profile

A pivotal phase III trial of Proxinium (VB4-847) in patients with head and neck cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Oportuzumab monatox (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 New trial record
    • 23 Jun 2015 As per a Viventia biotechnologies media release, the study is scheduled to begin in Q4 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top